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The relationship between obstructive sleep apnea (OSA) 
and chronic kidney disease (CKD) is the object of an 
increasing interest. OSA and CKD share some common 
risk factors, like older age and obesity, and both of them 
have complex interrelationships with conditions like 
systemic hypertension or diabetes, so that to some extent 
their joint occurrence may be expected. However, several 
mechanisms, like sympathetic hyperactivity, apnea-related 
hypertensive peaks, and oxidative stress with subclinical 
inflammation and endothelial dysfunction, could account 
for an independent harmful effect of OSA on the kidney, 
in addition to effects of comorbidities (1). In the last years, 
evidence has accumulated from both epidemiological and 
pathophysiological studies supporting some independent 
pathogenetic role of OSA in kidney disease.
About 30 years ago, based on small case series, a 
relationship was proposed between end-stage renal disease 
and sleep apnea (2). Thereafter, several epidemiological 
studies have been published which explored the association 
between OSA and CKD from different perspectives (OSA 
in CKD, CKD in OSA, OSA and CKD in diabetes) and 
with different experimental designs (cross-sectional, 
longitudinal, pre-post therapy, randomized controlled trial). 
Cross-sectional studies, mostly performed in patients 
recruited in sleep laboratories for suspected OSA, analysed 
estimated glomerular filtration rate (eGFR), albumin 
excretion, or, more rarely, both of them (3-9). Some 
relationship between OSA and CKD was found in most 
studies, but discordant data were often reported, especially 
about the possible correlates of CKD in OSA [apnea/
hypopnea index (AHI) or severity of nocturnal hypoxemia]. 
Longitudinal studies have mostly shown an increased 
incidence of CKD, or a faster decline in eGFR, in patients 
with OSA than in controls (10-14). However, they often 
lacked important information, i.e., data on severity of OSA 
and CKD, or on OSA treatment.
Studies on effects of OSA treatment by continuous 
positive airway pressure (CPAP) provided interesting 
additional data, mostly supporting some positive effects 
of treatment. Some studies demonstrated a decrease in 
albumin excretion after CPAP (15,16). GFR was reported 
to decrease after CPAP when it was high and associated 
with glomerular hyperfiltration before OSA treatment 
(17,18), and to increase (19), or decrease at a slower rate (20), 
when it was low. At variance with these studies, a recent 
randomized controlled trial has shown non-significant 
differences in eGFR decline between treated and untreated 
OSA subjects, although this negative result could be due to 
an insufficient sample size or to mild nocturnal hypoxemia 
at baseline (21).
Pathophysiological studies support a detrimental role 
of OSA. In patients with OSA, impaired renal vasodilating 
capacity (22) and increased renal vascular resistance 
(23,24) and filtration fraction (17,18) were reported, which 
could be related to increased intrarenal renin-angiotensin 
system (RAS) activation (18,25). While some alterations 
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were already observed in mild-moderate OSA (23), severe 
hypoxemia was associated with worse hemodynamic and 
functional renal impairment (17,25). 
In their study, Adams et al. cross-sectionally analysed the 
association between OSA, defined as AHI ≥10, and CKD in 
a large sample of men (26). Polysomnographic findings were 
typical of general population studies, i.e., a high prevalence of 
OSA (52.1%) with mild nocturnal hypoxemia [highest tertile 
of time spent with oxygen saturation (SaO2) <90%: ≥2.21%]. 
For their analyses, the authors accurately collected 
extensive information, including demographic data, clinical 
history (comorbidities, symptoms, drug therapy), and data 
on socioeconomic condition (workforce participation, 
household income, education) that had been disregarded 
in previous studies on this subject. They divided their 
population into three groups: normal kidney function 
(eGFR ≥90 mL/min/1.73 m2), mildly reduced kidney 
function (eGFR 60–89) and CKD (albumin/creatinine ratio 
≥3 mg/mmol and/or eGFR <60). Among demographic 
and biomedical factors, age, diabetes and smoking were 
significantly and independently associated to CKD. 
When considering polysomnographic indices, factors 
independently associated with CKD were AHI values 
exceeding different thresholds, the highest tertile of the 
respiratory arousal index (≥7.63), but not total arousal index 
or hypoxia parameters. 
One peculiarity of this study is that the subjects under 
analysis did not come from a sleep laboratory, but from the 
general population, unlike in most previous cross-sectional 
studies. One consequence was that in most subjects under 
investigation OSA, when present, was mild or moderate 
and, more than else, characterised by mild oxygen 
desaturations. Studies that found a relationship between 
hypoxemia and kidney function usually had populations 
where severe or protracted hypoxic levels were reached 
(6,7,9,10,16). Conversely, other studies reporting no effect 
of hypoxemia mainly included subjects with mild respiratory 
disorders and desaturations (8). One experimental study in 
humans demonstrated that the more severe hypoxemia, the 
greater the activation of the RAS and, therefore, the more 
likely a renal impairment (25). Longitudinal studies used 
a threshold of 12% night time with SaO2 <90% as cut-off 
to separate patients with and without accelerated eGFR 
decline (10). The only longitudinal study that did not find 
detrimental influence of OSA on eGFR decline was based 
on the Wisconsin cohort, which included only a small 
percentage of subjects with severe OSA (27). Therefore, the 
mild desaturations could explain the lack of a relationship 
between hypoxemia and CKD in Adams’ study.
The question arises whether OSA may be a risk factor 
for CKD in the absence of significant hypoxemia. OSA 
could exert some of its harmful effects through mechanisms 
like, for example, sleep fragmentation associated with apnea 
recurrence. However, in Adams’ study it remains unclear 
why AHI and respiratory arousal index were associated 
to CKD while total arousal index was not. Some studies 
observed significant associations between AHI and some 
parameters of kidney damage or dysfunction even when no 
effect of hypoxemia was found (5,12), whereas the opposite 
was reported by others (10,16). Further studies are needed 
to explore possible non-hypoxic mechanisms that may 
endanger the kidney in OSA.
An important aspect of the OSA-CKD relationship 
evaluated by Adams and coworkers was the clinical 
presentation of OSA in CKD. Loud snoring in OSA was 
more often reported by patients without than by those with 
CKD. Besides, among patients with CKD, as opposed to 
patients without CKD, witnessed apneas and loud snoring 
were reported similarly by patients with and without OSA. 
Likewise, a score corresponding to a high OSA risk at the 
STOP questionnaire was more frequently found in OSA 
than in non-OSA patients only if they were not affected by 
CKD (26). 
Similar findings were reported in another study (28) 
where, however, the OSA patients had been taken from a 
sleep laboratory population, so that they could represent 
a group preselected for OSA symptoms and risk factors. 
Instead, in Adams’ study all OSA subjects came from the 
general population (26), which demonstrates that OSA with 
coexistent CKD is really associated with fewer symptoms 
than isolated OSA, particularly as concerns snoring and 
witnessed apneas. Mild symptoms were already observed 
in OSA diagnosed after stroke or heart failure (29,30). 
That arises the question whether OSA symptoms are not 
perceived equally in patients with cardiovascular or renal 
diseases as opposed to OSA patients without comorbidities. 
Alternatively, obstructive apneas in these diseases may have 
different characteristics than in the general or in sleep 
laboratory populations, and generate more soft snoring 
that may make them less evident to bed partners. The most 
common OSA screening questionnaires proved poorly 
performant in CKD (31), and other screening tools have 
been advocated, as it was the case in other diseases, like 
stroke or diabetes (32,33). Developing new tools could 
have clinically important consequences, since the clinical 
course of CKD might improve if OSA is recognised and 
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treated. Although data in that respect are still uncertain, 
a preliminary analysis of our data suggests a benefit of 
treatment by fixed CPAP on eGFR in OSA (34). 
In clinical populations of suspected OSA patients, the 
link between OSA and CKD appeared stronger in female 
subjects (9,14). One limitation of Adams’ study is that it 
cannot provide any information on possible gender-related 
differences in the general population, since it included only 
male subjects (26).
To conclude, the study by Adams et al. may open 
perspectives for new investigations on OSA, both from a 
pathophysiological and a clinical point of view. It suggests 
the need of new studies on the role of non-hypoxic risk 
factors for CKD in OSA and on their pathophysiological 
mechanisms. Besides, it could open the way to the study of a 
new phenotype of OSA. Today, much interest is aroused by 
the variability of the clinical presentation of many diseases, 
including OSA, and by the management required by each 
of them. Several analyses have been performed in OSA 
that have identified highly different clinical clusters, often 
characterised by presence of comorbidities with poor OSA 
symptomatology (35). While some studies have underscored 
a decreased risk for hypertension in non-hypersomnolent 
OSA patients (36), other investigations have shown that 
OSA after stroke is characterised by poor symptoms 
but, in spite of that, may worsen life expectancy (37). 
OSA characterised by the association of CKD with rarely 
reported loud snoring and witnessed apneas could be a 
new phenotype with prognostic implications as regards 
the evolution of kidney dysfunction. The importance of 
paucisymptomatic OSA is still poorly understood and 
deserves great attention due to its very high prevalence. 
Results of new studies on poorly symptomatic OSA and on 
its therapy in patients with different comorbidities may have 
important implications for public health.
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